🔗 Visit the ClinicalTrials.gov page for NCT01590888
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. | Lancet Neurol | 2008 | 3.03 |
| 2 | PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. | J Alzheimers Dis | 2010 | 1.57 |
| 3 | Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. | Lancet Neurol | 2014 | 1.46 |
| 4 | The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders. | Front Pharmacol | 2014 | 0.91 |
| 5 | PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease. | J Huntingtons Dis | 2012 | 0.79 |